Technology
Health
Biotechnology

Otonomy

$2.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-1.47%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Otonomy and other stocks, options, ETFs, and crypto commission-free!

About

Otonomy, Inc. Common Stock, also called Otonomy, is a biopharmaceutical company, which engages in the development of therapeutics for neurotology. Read More The firm's product pipeline includes OTIVIDEX (dexamethasone) Ménière's disease; OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT); OTO-313 (gacyclidine) tinnitus; OTO-413 (BDNF) hidden hearing Loss; OTO-510 (otoprotectant) prevent CIHL; OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan in April 2008 and is headquartered in San Diego, CA.

Employees
49
Headquarters
San Diego, California
Founded
2008
Market Cap
83.77M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
176.12K
High Today
$2.82
Low Today
$2.63
Open Price
$2.74
Volume
40.45K
52 Week High
$4.85
52 Week Low
$1.50

Collections

Technology
Health
Biotechnology
Therapy
Biopharmaceutical
Pharmaceutical
2014 IPO
US

News

Simply Wall StMar 18

Is Otonomy, Inc. (NASDAQ:OTIC) Overpaying Its CEO?

David Weber has been the CEO of Otonomy, Inc. (NASDAQ:OTIC) since 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then we’ll look at a snap shot of the business growth. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This method should give us information to assess how appropriately the company pays the CEO. See our latest analysis for Otonomy How Does ...

15
Yahoo FinanceMar 11

Will Otonomy Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Otonomy. As of late, it has definitely been a great time to be an investor in Otonomy, Inc. OTIC. The stock has moved higher by 9.8% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider OTIC’s recent earnings estimate revision act...

107
Seeking AlphaMar 4

Otonomy (OTIC) CEO David Weber on Q4 2018 Results - Earnings Call Transcript

Otonomy (NASDAQ:OTIC) Q4 2018 Earnings Conference Call March 4, 2019 4:30 PM ET Company Participants Robert H. Uhl - Westwicke Partners David Weber - President, CEO Paul E. Cayer - Chief Financial & Business Officer Conference Call Participants Stacy Ku - Cowen and Company Pete Stavropoulos - Cantor Fitzgerald Fang-Ke Huang - SunTrust Robinson Humphrey Operator Good day, ladies and gentlemen, and welcome to the Q4 2018 Otonomy, Inc. Earnings Conference Call. [Operator Instructions] As a reminder, ...

21

Earnings

-$0.77
-$0.24
$0.29
$0.82
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.